A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT02367781 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

723

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Squamous Non-Small Cell Lung

Interventions

DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
DRUG: Carboplatin
DRUG: Nab-Paclitaxel
DRUG: Pemetrexed

Sponsor

Hoffmann-La Roche